Yazar "Temiz, Süleyman" için listeleme
-
Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study
Bilir, Cemil; Yıldız, İbrahim; Bilici, Ahmet; Uçar, Mahmut; Berk, Veli; Yıldız, Yaşar; Yazıcı, Ozan; İnanç İmamoğlu, Gökşen; Karadurmuş, Nuri; Pilancı, Kezban Nur; Arpacı, Erkan; Tanrıverdi, Özgür; Karcı, Ebru; Temiz, Süleyman; Nayır, Erdinç; Oktay, Esin; Dal, Pınar; Petekkaya, İbrahim; Varım, Ceyhun; Cinemre, Hakan (Taylor & Francis Inc., 2017)Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ...